President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

By Kamal Choudhury April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ...

Order calls on federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

President Donald Trump signed an executive order allowing the use of some psychedelic drugs to treat post-traumatic stress disorder. Flanked by Health and Human Services Secretary Robert F. Kennedy Jr ...

President Donald Trump signed an executive order that directs the FDA to accelerate their review of "psychedelics already designated as breakthrough therapy drugs." ...

The FDA announced efforts to expedite its research into perception-altering psychedelic medications.

By Kamal Choudhury and Christy Santhosh April 24 (Reuters) - The U.S. health regulator on Friday moved to speed up the development of new treatments for serious mental illness by awarding the national ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...

Like this article? Keep independent journalism alive. Support HuffPost. The Food and Drug Administration has announced efforts to expedite its research into perception-altering psychedelic medications ...